1. Show article details.

    BRIEF-Myokardia Doses First Patient In Phase 2 Clinical Trial Of Danicamtiv In Genetic Dilated Cardiomyopathy

    Reuters – 8:17 AM ET 09/09/2020

    MyoKardia Inc (MYOK): * MYOKARDIA DOSES FIRST PATIENT IN PHASE 2 CLINICAL TRIAL OF DANICAMTIV IN GENETIC DILATED CARDIOMYOPATHY. * MyoKardia Inc (MYOK) - TOPLINE DATA FROM PHASE 2 STUDY OF DANICAMTIV ARE ANTICIPATED IN SECOND HALF OF 2021 Source text for Eikon: Further company coverage:

  2. Show article details.

    MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

    GlobeNewswire – 8:00 AM ET 09/09/2020

    MyoKardia, Inc. (MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv in people with primary dilated cardiomyopathy thought to be caused by genetic mutations of the sarcomere. DCM is a disease of the myocardium characterized by left ventricular enlargement.

  3. Show article details.

    MyoKardia to Participate in September Investor Conferences

    GlobeNewswire – 8:00 AM ET 09/02/2020

    MyoKardia, Inc. (MYOK) today announced its participation in the following upcoming investor conferences: Webcasts of the presentations will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. A replay of each webcast will be available on the MyoKardia (MYOK) website for 90 days following each conference.

  4. Show article details.

    MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

    GlobeNewswire – 9:30 AM ET 08/29/2020

    EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet Presentation Expands on Positive Topline Results Showing Early, Sustained Reductions in Biomarkers of Cardiac Wall Stress and Myocardial Injury Mavacamten Demonstrated Broad Treatment Effect, with Consistent Benefit Across Primary and Secondary Endpoints Among All Prespecifi...

  5. Show article details.

    BRIEF-MyoKardia and LianBio Partner to Develop Mavacamten in Greater China

    Reuters – 8:25 AM ET 08/11/2020

    MyoKardia Inc (MYOK): * MYOKARDIA AND LIANBIO FORM STRATEGIC PARTNERSHIP TO DEVELOP AND COMMERCIALIZE MAVACAMTEN TOGETHER IN GREATER CHINA. * MyoKardia Inc (MYOK) - MYOKARDIA WILL A RECEIVE A PAYMENT OF $40 MILLION AT CLOSING. * MyoKardia Inc (MYOK) - MYOKARDIA MAY BE ELIGIBLE TO RECEIVE REGULATORY AND SALES MILESTONE PAYMENTS OF UP TO $147.5 MILLION.

  6. Show article details.

    MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

    GlobeNewswire – 7:35 AM ET 08/11/2020

    Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation:  MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, Calif., Aug. 11, 2020 -- MyoKardia, Inc. (MYOK) and LianBio announced today that they have entered into a strategic collaboration to de...

  7. Show article details.

    Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020

    GlobeNewswire – 4:05 PM ET 08/10/2020

    MyoKardia, Inc. (MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker session at the upcoming European Society of Cardiology Congress 2020.

  8. Show article details.

    MyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

    GlobeNewswire – 4:05 PM ET 08/05/2020

    MyoKardia, Inc. (MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET.

  9. Show article details.

    BRIEF-Myokardia Reports Second Quarter 2020 Financial Results

    Reuters – 5:09 PM ET 08/04/2020

    MyoKardia Inc (MYOK): * MYOKARDIA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS. * Q2 LOSS PER SHARE $1.27. * Q2 EARNINGS PER SHARE ESTIMATE $-1.46 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  10. Show article details.

    MyoKardia Reports Second Quarter 2020 Financial Results

    GlobeNewswire – 4:05 PM ET 08/04/2020

    MyoKardia, Inc. (MYOK), today reported financial results for the second quarter ended June 30, 2020.

  11. Show article details.

    CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

    GlobeNewswire – 9:52 AM ET 08/03/2020

    In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (MYOK), please note that the second quote by Jeffrey B. Geske, M.D. has changed. MyoKardia, Inc. (MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. HCM is the most common genetic cardiomyopathy, estimated to affect one in every five hundred people.

  12. Show article details.

    BRIEF-Myokardia Doses First Patient In Phase 3 Valor-Hcm Trial Of Mavacamten

    Reuters – 8:47 AM ET 08/03/2020

    MyoKardia Inc (MYOK): * MYOKARDIA DOSES FIRST PATIENT IN PHASE 3 VALOR-HCM TRIAL OF MAVACAMTEN. * MYOKARDIA DOSES FIRST PATIENT IN PHASE 3 VALOR-HCM TRIAL OF MAVACAMTEN Source text for Eikon: Further company coverage:

  13. Show article details.

    MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

    GlobeNewswire – 8:30 AM ET 08/03/2020

    MyoKardia, Inc. (MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. HCM is the most common genetic cardiomyopathy, estimated to affect one in every five hundred people.

  14. Show article details.

    MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020

    GlobeNewswire – 8:00 AM ET 07/28/2020

    MyoKardia, Inc. (MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020. Conference Call and WebcastAnalysts and investors are invited to participate in the conference call by calling 844-494-0193 from the U.S. and Canada or 508-637-5584 internationally and using the conference ID 4340819.

  15. Show article details.

    BRIEF-Myokardia Announces Receipt Of Breakthrough Therapy Designation From FDA For Mavacamten

    Reuters – 5:58 PM ET 07/23/2020

    MyoKardia Inc (MYOK): * MYOKARDIA ANNOUNCES RECEIPT OF BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR MAVACAMTEN FOR THE TREATMENT OF SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY. * MYOKARDIA (MYOK) - CURRENTLY PREPARING A NEW DRUG APPLICATION FOR MAVACAMTEN, WITH PLANS TO SUBMIT TO FDA IN Q1 OF 2021 Source text for Eikon: Further company coverage:

  16. Show article details.

    MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy

    GlobeNewswire – 4:05 PM ET 07/23/2020

    MyoKardia, Inc. (MYOK) today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy.

  17. Show article details.

    BRIEF-Myokardia And Fulcrum Therapeutics Announce Multi-Target Collaboration To Discover Novel Targeted Therapies For Genetic Cardiomyopathies

    Reuters – 7:43 AM ET 07/21/2020

    Fulcrum Therapeutics Inc (FULC): * MYOKARDIA AND FULCRUM THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO DISCOVER NOVEL TARGETED THERAPIES FOR GENETIC CARDIOMYOPATHIES. * Fulcrum Therapeutics Inc (FULC) - FULCRUM WILL RECEIVE A PAYMENT OF $12.5 MILLION AT CLOSE. * FULCRUM THERAPEUTICS (FULC) - FULCRUM MAY BE ELIGIBLE TO RECEIVE MILESTONE PAYMENTS AND ADDITIONAL RESEARCH REIMBURSEMENT OF UP TO $302.5 MILLION.

  18. Show article details.

    MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

    GlobeNewswire – 7:30 AM ET 07/21/2020

    MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that they have entered into a strategic collaboration and licens...

  19. Show article details.

    MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

    GlobeNewswire – 7:30 AM ET 07/21/2020

    MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that they have entered into a strategic collaboration and licens...

  20. Show article details.

    BRIEF-Myokardia Announces Appointment Of Denelle J. Waynick As General Counsel And Corporate Secretary

    Reuters – 8:21 AM ET 07/06/2020

    MyoKardia Inc (MYOK): * MYOKARDIA ANNOUNCES APPOINTMENT OF DENELLE J. WAYNICK AS GENERAL COUNSEL AND CORPORATE SECRETARY Source text for Eikon: Further company coverage:

Page:

Today's and Upcoming Events

  • Nov
    02

    MYOK to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    04

    MYOK announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.